Personalis (NASDAQ:PSNL) CEO Christopher Hall Sells 80,091 Shares

Personalis, Inc. (NASDAQ:PSNL – Get Free Report) CEO Christopher Hall sold 80,091 shares of Personalis stock in a transaction on Friday, May 29th. The stock was sold at an average price of $11.02, for a total transaction of $882,602.82. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $2,600,565.72. This represents a 25.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Price Performance

NASDAQ PSNL traded up $0.42 during mid-day trading on Friday, reaching $11.40. 4,471,474 shares of the stock were exchanged, compared to its average volume of 2,505,722. Personalis, Inc. has a one year low of $3.84 and a one year high of $11.85. The stock has a 50 day simple moving average of $6.86 and a 200-day simple moving average of $8.10. The stock has a market cap of $1.19 billion, a P/E ratio of -11.18 and a beta of 1.96.

Get Personalis alerts:

Personalis (NASDAQ:PSNL – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.49 million. Sell-side analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. grew its holdings in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after buying an additional 7,896,714 shares during the last quarter. ARK Investment Management LLC boosted its holdings in Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares during the last quarter. Aberdeen Group plc boosted its holdings in Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares during the last quarter. Kennedy Capital Management LLC boosted its holdings in Personalis by 196.2% during the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after purchasing an additional 1,281,695 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Personalis by 1,332.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after purchasing an additional 1,347,439 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. BTIG Research dropped their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Morgan Stanley cut their price objective on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Needham & Company LLC increased their price objective on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.00.

Get Our Latest Stock Analysis on PSNL

About Personalis

(Get Free Report)

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.

Read More

• Five stocks we like better than Personalis
• Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
• Salesforce Stock Finds Support as AI Momentum Builds
• Dollar Tree Keeps Winning After Family Dollar Divorce
• Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.